XOR-mediated tumor-selective nanomaterial therapy: achieving tumor and immune cell dual regulation through intracellular ROS generation.

J Nanobiotechnology · 2026 · PMC13011489 · PMID 41689099

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

We further confirmed by western blot that the level of M1 activation key factor phosphorylation of STAT1 (p-STAT1) significantly increased in the ZIF-8@XOR group, while M2 activation factor phosphorylation of STAT6 (p-STAT6) exhibited a decreasing trend (Fig. 4 C).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.